
Nanosurface Biomedical Inc Profile last edited on: 9/20/2022
CAGE: 7C8Q3
UEI: D6VABZ7RVM84
Business Identifier: Biomimetic cultureware for biomedical and research applications Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
13757 26th Avenue Ne
Seattle, WA 98125
Seattle, WA 98125
(206) 604-9280 |
contact@nsurfacebio.com |
www.nanosurfacebio.com |
Location: Single
Congr. District: 07
County: King
Congr. District: 07
County: King
Public Profile
NanoSurface Biomedical provides products and services for drug development, disease modeling, and fundamental research into cell biology. NanoSurface culture products imitate the native extracellular matrix, and structure cultured cells into physiologically relevant tissue models. The firm develop nanopattern substrates that are printed at the bottom of sterile cell culture dishes - effectively providing a topographical and mechanical niche for cells to grow as if they were in vivo. By mimicking the extracellular environment, this unique Anisotropically NanoFabricated Substratum (ANFS) technology promotes the in vivo-like maturation and alignment of in vitro cell cultures. The NanoSurface Biomedical's nanopatterned cultureware has been validated on various cell types toincluude cardiomyocytes, muscle cells, entothelial cells, iPS cells, mesenchymal stem cells and fibroblasts in in vitro cell cultures.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $2,259,388 | |
Project Title: Predictive Assessment of Acute and Chronic Cardiotoxicity Using Combinatorially Matured hPSC-CMs | ||||
2021 | 2 | NIH | $1,968,756 | |
Project Title: Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | ||||
2020 | 1 | NIH | $252,131 | |
Project Title: Maturation Of Stem Cell-Derived Cardiomyocytes Using A Simulated Microgravity Bioreactor And Combinations Of Extracellular Developmental Cues | ||||
2020 | 1 | NIH | $252,131 | |
Project Title: Cryopreserving Stem Cell-Derived Cardiomyocytes in Ready-To-Use Assay Plates for Improved Reproducibility of Drug Toxicity Testing | ||||
2019 | 1 | NIH | $225,000 | |
Project Title: A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells |
Key People / Management
Martyn Darby
Eli Fine
Elliot Fisher
Nicholas A Geisse
Rajneesh Jah
Alec Simon Tulloch Smith
Eli Fine
Elliot Fisher
Nicholas A Geisse
Rajneesh Jah
Alec Simon Tulloch Smith
Company News
There are no news available.